Extension Study of Zemaira® i.v. Administration in Subjects With Emphysema Due to alpha1-proteinase Inhibitor Deficiency.

Overview

This study is a continuation of the placebo-controlled study CE1226_4001 (NCT00261833) to evaluate the efficacy and safety of Zemaira® intravenous (i.v). administration in subjects with emphysema due to alpha1-proteinase inhibitor deficiency. The long-term verification of a disease-modifying benefit of Zemaira® on the progression of emphysema will be assessed by volume-adjusted lung density, measured yearly by computed tomography (CT).

Full Title of Study: “An Open-label, Non-controlled, Multicenter, Multinational Study to Evaluate the Efficacy and Safety of Zemaira® Administration in Chronic Augmentation and Maintenance Therapy in Subjects With Emphysema Due to alpha1-proteinase Inhibitor Deficiency Who Completed Clinical Study CE1226_4001”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: September 2014

Interventions

  • Biological: Alpha1- proteinase inhibitor [human]
    • Lyophilized preparation of 60 mg/kg body weight intravenously once per week

Arms, Groups and Cohorts

  • Experimental: Zemaira®

Clinical Trial Outcome Measures

Primary Measures

  • Rate of Change of Adjusted Lung Density
    • Time Frame: Up to 2 years
    • As measured by centralized, standardized computer tomographic (CT) lung densitometry. CT scans were acquired at 2 inspiration states: TLC (Total Lung Capacity; ie, full inspiration) and FRC (Functional Residual Capacity; ie, full expiration). Results were adjusted for total lung volume and are presented as point estimates for the average rate of decline in the early start and delayed start subgroups from a linear random regression model with country, inspiration state (only for ‘TLC and FRC state’), time (time elapsed since Day 1 [CE1226_4001]), treatment and treatment by time interaction as fixed effects and subject and subject by time interaction as random coefficients.

Secondary Measures

  • Absolute Change in Adjusted Lung Density
    • Time Frame: From baseline to 2 years
    • Absolute change from baseline to 2 years as measured by centralized, standardized CT lung densitometry. CT scans were acquired at 2 inspiration states: TLC (ie, full inspiration) and FRC (ie, full expiration). Results were adjusted for total lung volume and are presented as point estimates for the average absolute change in the early start and delayed start subgroups from an analysis of covariance (ANCOVA) model with country, treatment, and baseline lung density as fixed effects and inspiration state as a repeated random effect. The baseline is the last assessment from the preceding study CE1226_4001.
  • Percent Change in Adjusted Lung Density
    • Time Frame: From baseline to 2 years
    • Percent change from baseline to 2 years as measured by centralized, standardized CT lung densitometry. CT scans were acquired at 2 inspiration states: TLC (ie, full inspiration) and FRC (ie, full expiration). Results were adjusted for total lung volume and are presented as point estimates for the average percent change in the early start and delayed start subgroups from an analysis of covariance (ANCOVA) model with country, treatment, and baseline lung density as fixed effects and inspiration state as a repeated random effect. The baseline is the last assessment from the preceding study CE1226_4001.
  • Change in Subject-reported Symptoms
    • Time Frame: From baseline to 2 years
    • Patient-reported symptoms were measured using the St George’s Respiratory Questionnaire (SGRQ). SGRQ total, symptoms, activity and impact scores range from 0 to 100, with higher scores indicating more limitations, and change from baseline below zero (0) is favorable, indicating improvement.
  • Percent Change in Lung Function as Measured by Forced Expiratory Volume in 1 Second (FEV1)
    • Time Frame: From baseline up to 2 years
  • Percent Change in Lung Function as Measured by Ratio of FEV1/FVC (Forced Vital Capacity)
    • Time Frame: From baseline up to 2 years
  • Percent Change in Lung Function as Measured by Percent Predicted FEV1
    • Time Frame: From baseline up to 2 years
  • Number of Subjects With Pulmonary Exacerbations
    • Time Frame: Up to 2 years
  • Annual Rate in Subject Years of Pulmonary Exacerbations
    • Time Frame: Up to 2 years
    • Annual exposure-adjusted incidence rate of pulmonary exacerbations.
  • Time to First Pulmonary Exacerbation
    • Time Frame: Up to 2 years
  • Percentage of Subjects With Treatment Emergent Adverse Events
    • Time Frame: From baseline up to 2.5 years
    • Percentage of subjects with treatment-emergent adverse events (TEAEs): overall, by severity, by relatedness, by seriousness, and which occurred within 24 hours of Zemaira administration.

Participating in This Clinical Trial

Inclusion Criteria

  • Subjects who have completed the 2-year treatment and observation period in the Phase 3/4 Zemaira® CE1226_4001 study (NCT00261833) and are willing to sign informed consent – Males, and non-pregnant, non-lactating females, whose screening pregnancy test is negative and who are using contraceptive methods deemed reliable by the investigator Exclusion Criteria:

  • Individuals residing in the US – Current evidence of alcohol abuse or abuse of drugs such as barbiturates, benzodiazepines, amphetamines, cocaine, opioids, and cannabinoids – History of allergy, anaphylactic reaction, or severe systemic response to human plasma derived products, or known mannitol hypersensitivity, or history of prior adverse reaction to mannitol – Current tobacco smoker (smoking must be discontinued for at least 6 months prior to study participation) – Conditions or behaviors that interfere with attending scheduled study visits in the opinion of the investigator – History of non-compliance – Administration of any other experimental new drug or participation in an investigation of a marketed product – Inability to perform necessary study procedures

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • CSL Behring
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Program Director, Clinical R&D, Study Director, CSL Behring

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.